{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:11:48Z","timestamp":1791821508993,"version":"4.3.4"},"reference-count":23,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,2,28]]},"abstract":"\n Importance<\/jats:title>\n Previous studies suggested a benefit of argatroban plus alteplase (recombinant tissue-type plasminogen activator) in patients with acute ischemic stroke (AIS). However, robust evidence in trials with large sample sizes is lacking.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess the efficacy of argatroban plus alteplase for AIS.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This multicenter, open-label, blinded end point randomized clinical trial including 808 patients with AIS was conducted at 50 hospitals in China with enrollment from January 18, 2019, through October 30, 2021, and final follow-up on January 24, 2022.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Eligible patients were randomly assigned within 4.5 hours of symptom onset to the argatroban plus alteplase group (n\u2009=\u2009402), which received intravenous argatroban (100 \u03bcg\/kg bolus over 3-5 minutes followed by an infusion of 1.0 \u03bcg\/kg per minute for 48 hours) within 1 hour after alteplase (0.9 mg\/kg; maximum dose, 90 mg; 10% administered as 1-minute bolus, remaining infused over 1 hour), or alteplase alone group (n\u2009=\u2009415), which received intravenous alteplase alone. Both groups received guideline-based treatments.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary end point was excellent functional outcome, defined as a modified Rankin Scale score (range, 0 [no symptoms] to 6 [death]) of 0 to 1 at 90 days. All end points had blinded assessment and were analyzed on a full analysis set.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 817 eligible patients with AIS who were randomized (median [IQR] age, 65 [57-71] years; 238 [29.1%] women; median [IQR] National Institutes of Health Stroke Scale score, 9 [7-12]), 760 (93.0%) completed the trial. At 90 days, 210 of 329 participants (63.8%) in the argatroban plus alteplase group vs 238 of 367 (64.9%) in the alteplase alone group had an excellent functional outcome (risk difference, \u22121.0% [95% CI, \u22128.1% to 6.1%]; risk ratio, 0.98 [95% CI, 0.88-1.10];\n P<\/jats:italic>\n \u2009=\u2009.78). The percentages of participants with symptomatic intracranial hemorrhage, parenchymal hematoma type 2, and major systemic bleeding were 2.1% (8\/383), 2.3% (9\/383), and 0.3% (1\/383), respectively, in the argatroban plus alteplase group and 1.8% (7\/397), 2.5% (10\/397), and 0.5% (2\/397), respectively, in the alteplase alone group.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Among patients with acute ischemic stroke, treatment with argatroban plus intravenous alteplase compared with alteplase alone did not result in a significantly greater likelihood of excellent functional outcome at 90 days.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT03740958<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2023.0550","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T11:00:54Z","timestamp":1675940454000},"page":"640","source":"Crossref","is-referenced-by-count":73,"title":["Effect of Argatroban Plus Intravenous Alteplase vs Intravenous Alteplase Alone on Neurologic Function in Patients With Acute Ischemic Stroke"],"prefix":"10.1001","volume":"329","author":[{"given":"Hui-Sheng","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Neurology, General Hospital of Northern Theatre Command, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Neurology, General Hospital of Northern Theatre Command, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-He","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Neurology, General Hospital of Northern Theatre Command, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Jie","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Neurology, General Hospital of Northern Theatre Command, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gao-Hua","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, Liaoning Health Industry Group Fukuang General Hospital, Fushun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-Long","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Affiliated Nanshi Hospital of Henan University, Nanyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tieling County Central Hospital, Tieling, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Dong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tonghua Vascular Disease Hospital, Tonghua, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Mei","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tonghua Vascular Disease Hospital, Tonghua, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Hao","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Lvshunkou Traditional Chinese Medicine Hospital, Dalian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Cheng","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Anyang People\u2019s Hospital, Anyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Jie","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Liaoning Health Industry Group Fuxinkuang General Hospital, Fuxin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Bin","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Neurology, Haicheng Traditional Chinese Medicine Hospital, Haicheng, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Wei","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Anshan Changda Hospital, Anshan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Xian","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tianjin Beichen Traditional Chinese Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Lin","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Neurology, Panjin Central Hospital, Panjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nanyang Central Hospital, Nanyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Er-Qiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Fuqing Hospital, Fuqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Hua","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye-Fang","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huludao Second People\u2019s Hospital, Huludao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Yun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Liaocheng Brain Hospital, Liaocheng, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren-Lin","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Neurology, Wafangdian Third Hospital, Dalian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He-Ping","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Guangxi Zhuang Autonomous Region People\u2019s Hospital, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duo-Lao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Long","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ARAIS Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Wen","family":"Liu","sequence":"additional","affiliation":[{"name":"for the ARAIS Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Long","family":"Chen","sequence":"additional","affiliation":[{"name":"for the ARAIS Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Zhe","family":"Yu","sequence":"additional","affiliation":[{"name":"for the ARAIS Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Man","family":"Huang","sequence":"additional","affiliation":[{"name":"for the ARAIS Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian-Qiang","family":"Wang","sequence":"additional","affiliation":[{"name":"for the ARAIS Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Mei","family":"Geng","sequence":"additional","affiliation":[{"name":"for the ARAIS Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Huo","family":"Chen","sequence":"additional","affiliation":[{"name":"for the ARAIS Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Zhong","family":"Wang","sequence":"additional","affiliation":[{"name":"for the ARAIS Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zou","sequence":"additional","affiliation":[{"name":"for the ARAIS Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Ling","family":"Hu","sequence":"additional","affiliation":[{"name":"for the ARAIS Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Wang","sequence":"additional","affiliation":[{"name":"for the ARAIS Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Yong","family":"Zhang","sequence":"additional","affiliation":[{"name":"for the ARAIS Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zai-Hui","family":"Zhang","sequence":"additional","affiliation":[{"name":"for the ARAIS Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Jiang","sequence":"additional","affiliation":[{"name":"for the ARAIS Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Yun","family":"Wang","sequence":"additional","affiliation":[{"name":"for the ARAIS Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Fang","family":"Wu","sequence":"additional","affiliation":[{"name":"for the ARAIS Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run-Hui","family":"Li","sequence":"additional","affiliation":[{"name":"for the ARAIS Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Sheng","family":"Wang","sequence":"additional","affiliation":[{"name":"for the ARAIS Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yu","sequence":"additional","affiliation":[{"name":"for the ARAIS Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[{"name":"for the ARAIS Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui-Hua","family":"Yang","sequence":"additional","affiliation":[{"name":"for the ARAIS Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[{"name":"for the ARAIS Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Jun","family":"Wang","sequence":"additional","affiliation":[{"name":"for the ARAIS Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Hai","family":"Wang","sequence":"additional","affiliation":[{"name":"for the ARAIS Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run-Xiu","family":"Zhu","sequence":"additional","affiliation":[{"name":"for the ARAIS Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Qiang","family":"Wen","sequence":"additional","affiliation":[{"name":"for the ARAIS Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Jun","family":"Cao","sequence":"additional","affiliation":[{"name":"for the ARAIS Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-Da","family":"Zhou","sequence":"additional","affiliation":[{"name":"for the ARAIS Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hai","family":"Yang","sequence":"additional","affiliation":[{"name":"for the ARAIS Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"joi230005r1","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1161\/STR.0000000000000211","article-title":"Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association.","volume":"50","author":"Powers","year":"2019","journal-title":"Stroke"},{"issue":"3","key":"joi230005r2","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1161\/01.STR.0000258112.14918.24","article-title":"The impact of recanalization on ischemic stroke outcome: a meta-analysis.","volume":"38","author":"Rha","year":"2007","journal-title":"Stroke"},{"issue":"6","key":"joi230005r3","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1212\/WNL.59.6.862","article-title":"Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator.","volume":"59","author":"Alexandrov","year":"2002","journal-title":"Neurology"},{"issue":"10029","key":"joi230005r4","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/S0140-6736(16)00163-X","article-title":"Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials.","volume":"387","author":"Goyal","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"joi230005r5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1161\/01.STR.0000251800.01964.f6","article-title":"Clinical deterioration after intravenous recombinant tissue plasminogen activator treatment: a multicenter transcranial Doppler study.","volume":"38","author":"Saqqur","year":"2007","journal-title":"Stroke"},{"issue":"10","key":"joi230005r6","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1080\/01616412.2018.1495882","article-title":"Argatroban plus aspirin versus aspirin in acute ischemic stroke.","volume":"40","author":"Chen","year":"2018","journal-title":"Neurol Res"},{"issue":"5","key":"joi230005r7","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s00415-006-0365-y","article-title":"Efficacy of anti-coagulant treatment with argatroban on cardioembolic stroke.","volume":"254","author":"Hosomi","year":"2007","journal-title":"J Neurol"},{"issue":"6","key":"joi230005r8","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1161\/01.RES.67.6.1552","article-title":"In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator.","volume":"67","author":"Jang","year":"1990","journal-title":"Circ Res"},{"issue":"11","key":"joi230005r9","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1161\/hs1101.097390","article-title":"Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke.","volume":"32","author":"Morris","year":"2001","journal-title":"Stroke"},{"issue":"3","key":"joi230005r10","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1161\/STROKEAHA.111.625574","article-title":"The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study.","volume":"43","author":"Barreto","year":"2012","journal-title":"Stroke"},{"issue":"6","key":"joi230005r11","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1161\/STROKEAHA.117.016720","article-title":"Randomized, multicenter trial of ARTSS-2 (argatroban with recombinant tissue plasminogen activator for acute stroke).","volume":"48","author":"Barreto","year":"2017","journal-title":"Stroke"},{"issue":"12","key":"joi230005r12","doi-asserted-by":"publisher","first-page":"3647","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.08.036","article-title":"Safety and feasibility of argatroban, recombinant tissue plasminogen activator, and intra-arterial therapy in stroke (ARTSS-IA study).","volume":"27","author":"Berekashvili","year":"2018","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"3","key":"joi230005r13","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1161\/STROKEAHA.113.004488","article-title":"Direct thrombin inhibitor argatroban reduces stroke damage in 2 different models.","volume":"45","author":"Lyden","year":"2014","journal-title":"Stroke"},{"key":"joi230005r14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ahj.2020.04.003","article-title":"Randomized trial of argatroban plus recombinant tissue-type plasminogen activator for acute ischemic stroke (ARAIS): rationale and design.","volume":"225","author":"Yang","year":"2020","journal-title":"Am Heart J"},{"issue":"8","key":"joi230005r15","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1001\/archneur.63.8.1057","article-title":"Argatroban tPA stroke study: study design and results in the first treated cohort.","volume":"63","author":"Sugg","year":"2006","journal-title":"Arch Neurol"},{"issue":"6","key":"joi230005r16","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1161\/01.STR.0000016323.13456.E5","article-title":"Thrombolysis-related hemorrhagic infarction: a marker of early reperfusion, reduced infarct size, and improved outcome in patients with proximal middle cerebral artery occlusion.","volume":"33","author":"Molina","year":"2002","journal-title":"Stroke"},{"issue":"9","key":"joi230005r17","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1161\/01.STR.0000027861.75884.DF","article-title":"Prediction of early neurological deterioration using diffusion- and perfusion-weighted imaging in hyperacute middle cerebral artery ischemic stroke.","volume":"33","author":"Arenillas","year":"2002","journal-title":"Stroke"},{"issue":"7","key":"joi230005r18","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1161\/STR.0b013e318296aeca","article-title":"An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association\/American Stroke Association.","volume":"44","author":"Sacco","year":"2013","journal-title":"Stroke"},{"issue":"9","key":"joi230005r19","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1161\/STROKEAHA.114.005135","article-title":"Defining clinically relevant cerebral hemorrhage after thrombolytic therapy for stroke: analysis of the National Institute of Neurological Disorders and Stroke tissue-type plasminogen activator trials.","volume":"45","author":"Rao","year":"2014","journal-title":"Stroke"},{"issue":"11","key":"joi230005r20","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1161\/01.STR.30.11.2280","article-title":"Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort.","volume":"30","author":"Fiorelli","year":"1999","journal-title":"Stroke"},{"issue":"7","key":"joi230005r21","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1177\/1747493020978345","article-title":"The multiarm optimization of stroke thrombolysis phase 3 acute stroke randomized clinical trial: rationale and methods.","volume":"16","author":"Deeds","year":"2021","journal-title":"Int J Stroke"},{"issue":"3","key":"joi230005r22","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1136\/svn-2020-000337","article-title":"Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: the first multicentre, phase III trial in China.","volume":"5","author":"Zheng","year":"2020","journal-title":"Stroke Vasc Neurol"},{"issue":"1","key":"joi230005r23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/svn-2021-000978","article-title":"Safety and efficacy of tenecteplase versus alteplase in patients with acute ischaemic stroke (TRACE): a multicentre, randomised, open label, blinded-endpoint (PROBE) controlled phase II study.","volume":"7","author":"Li","year":"2022","journal-title":"Stroke Vasc Neurol"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2801517\/jama_chen_2023_oi_230005_1681227566.55764.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T11:09:50Z","timestamp":1681297790000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2801517"}},"subtitle":["The ARAIS Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,2,28]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2023.0550","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,28]]}}}